Clinical Trial: Studies of Neurological Paraneoplastic Syndromes
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Studies of Neurological Paraneoplastic Syndromes
Brief Summary: This study is for patients with cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome.
Detailed Summary:
Patients usually go to their doctors with neurological complaints and later find they have cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome. Paraneoplastic syndromes are rare conditions in which the immune system is involved in causing brain damage and fighting cancer.
Such patients with paraneoplastic neurologic degenerations(PNDs) may have autoantibodies, an antibody or protein the immune system creates that is directed against his or her own proteins. This study aims to better understand PNDS by:
- analyzing for autoantibodies in serum and cerebral spinal fluid
- analyzing for antigen specificity and for antigens in cancer tissue
- comparing PND autoantibodies with those in cancer patients but no PND
- comparing PND autoantibodies with those in PND patients but no cancer
- studying the immune performance of patients with PNDs
As this study is not a treatment study, tissues for this study will only come from procedures necessary for the patient's treatment.
Sponsor: Memorial Sloan Kettering Cancer Center
Current Primary Outcome: Increase understanding of PNDS [ Time Frame: Ongoing ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Memorial Sloan Kettering Cancer Center
Dates:
Date Received: December 21, 2007
Date Started: April 1988
Date Completion:
Last Updated: March 27, 2009
Last Verified: March 2009
